Mineralys Therapeutics Bolsa (NASDAQ: MLYS)

Últimas noticias sobre Mineralys Therapeutics (NASDAQ:MLYS) Bolsa

MINERALYS THERAPEUTICS INC

Mineralys Therapeutics

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ACON

ACTG

ALUR

BTAI

CNTA

DALN

DWTX

EVAX

FFBC

HYZN

LITM

MLYS

NVNI

PBBK

SEPN

STBX

TRUG

TWLO

Twilio sube un 18,5% tras superar expectativas de ingresos. Explora los movimientos clave del mercado previo de hoy.

Acciones de Twilio (TWLO) se disparan más de un 18%; 20 acciones que se mueven en el premercado de EE.UU.

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics Inc

Raymond James analyst Buck Horne downgrades Mid-America Apartment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MAA#NYSE">MAA</a>) from Strong Buy to Outperform and lowers the price target from $185 to $175.

Downgrades

Price Target

Analyst Ratings

Raymond James Downgrades Mid-America Apartment to Outperform, Lowers Price Target to $175

General

COIN

Watching Coinbase; Chief Legal Officer Reportedly Says Reported SEC investigation Is A Hold-Over From Prior Administration About A Metric We Stopped Reporting 2.5 Years Ago; Verified Users Metric Includes Anyone Who Verified Their Email Address Or Phone Number With Us; Strongly Believe SEC Investigation Should Not Continue, Remain Committed To Working To Bring The Matter To A Close

Raymond James analyst Buck Horne downgrades NexPoint Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NXRT#NYSE">NXRT</a>) from Outperform to Market Perform.

NXRT

Raymond James Downgrades NexPoint Residential to Market Perform

Raymond James analyst Buck Horne upgrades Center (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSR#NYSE">CSR</a>) from Outperform to Strong Buy and raises the price target from $66 to $69.

Upgrades

Raymond James Upgrades Center to Strong Buy, Raises Price Target to $69

Telsey Advisory Group analyst Dana Telsey maintains European Wax Center (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWCZ#NASDAQ">EWCZ</a>) with a Market Perform and maintains $5 price target.

EWCZ

Telsey Advisory Group Maintains Market Perform on European Wax Center, Maintains $5 Price Target

Raymond James analyst Savanthi Syth downgrades JetBlue Airways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) from Outperform to Market Perform.

JBLU

Raymond James Downgrades JetBlue Airways to Market Perform

Raymond James analyst Savanthi Syth downgrades Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) from Outperform to Market Perform.

AZUL

Raymond James Downgrades Azul to Market Perform

Nextracker Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) reported better-than-expected fourth-quarter financial results and <a href="https://www.benzinga.com/quote/NXT/earnings">issued FY26 sales guidance above estimates.</a>
NEXTracker posted adjusted earnings of $1.29 per share, beating market estimates of 98 cents per share. The company's quarterly sales came in at $924.00 million versus expectations of $828.84 million.
&#8220;We had a fantastic year, exceeding our financial, technology, customer satisfaction, and market growth targets,&#8221; said Dan Shugar, founder and CEO of Nextracker. &#8220;We posted another strong bookings quarter with backlog again increasing sequentially, supported by robust demand around the globe.&#8221;
NEXTracker said it sees FY2026 adjusted EPS of $3.65-$4.03 and sales of $3.200 billion to $3.400 billion.
Additionally, the company announced it acquired Bentek Corp for $78 million and several firms raised their respective price targets on the stock.
Nextracker shares gained 10.4% to trade at $60.75 on Thursday.
These analysts made changes to their price targets on Nextracker following earnings announcement.
<ul class="wp-block-list">
<li>BMO Capital analyst Ameet Thakkar maintained NEXTracker with a Market Perform and raised the price target from $51 to $59.</li>
<li>B of A Securities analyst Dimple Gosa maintained the stock with a Buy and raised the price target from $55 to $65.</li>
<li>Truist Securities analyst Jordan Levy maintained NEXTracker with an Overweight and raised the price target from $49 to $65.</li>
<li>Susquehanna analyst Biju Perincheril maintained NEXTracker with a Positive and raised the price target from $54 to $66.</li>
<li>Goldman Sachs analyst Brian Lee maintained the stock with a Buy and boosted the price target from $61 to $68.</li>
<li>Roth Capital analyst Philip Shen reiterated NEXTracker with a Buy and raised the price target from $55 to $70.</li>
</ul>
Considering buying NXT stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="575" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15134720/image-187-1024x575.png" alt="" class="wp-image-916957" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15134720/image-187-1024x575.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15134720/image-187-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15134720/image-187-768x431.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15134720/image-187.png 1127w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Earnings

These Analysts Increase Their Forecasts On NEXTracker After Upbeat Results

Telsey Advisory Group analyst Cristina Fernandez maintains Foot Locker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FL#NYSE">FL</a>) with a Market Perform and maintains $20 price target.

Telsey Advisory Group Maintains Market Perform on Foot Locker, Maintains $20 Price Target

Roth MKM analyst Nick Anderson maintains Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) with a Buy and lowers the price target from $9 to $7.5.

ISPR

Roth MKM Maintains Buy on Ispire Technology, Lowers Price Target to $7.5

President Donald Trump <a href="https://www.youtube.com/watch?v=6tBiXMMTdrM&amp;t=13s">said</a> that revenue from tariffs could potentially eliminate the need for the federal income tax, citing the period from 1870 to 1913 when tariffs were the primary source of federal income and the nation experienced significant prosperity.
<h2 class="wp-block-heading">Record Revenue Meets Real-World Roadblocks</h2>
That claim to Fox News comes as U.S. customs duties surged to a historic high in April. The<a href="https://www.fiscal.treasury.gov/files/reports-statements/mts/mts0425.pdf"> Treasury Department </a>reported collecting a record $16.3 billion in customs duties—driven by steep new tariffs—marking the highest single-month total ever recorded.
April&#8217;s spike followed the rollout of <a href="https://www.benzinga.com/personal-finance/25/03/44237846/trump-proposes-special-a-gold-card-for-wealthy-immigrants-that-costs-5-million-says-selling-enou">Trump&#8217;s</a> newly enacted tariffs, including a 25% steel tariff and a sweeping 10% universal tariff that went into effect on April 2.
Don't Miss:
<ul class="wp-block-list">
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Still, the broader financial picture tells a different story. As of March, The Treasury has already reached the current debt limit of $36.1 trillion, according to<a href="https://www.cbo.gov/publication/61265"> the Congressional Budget Office</a>. The federal deficit reached<a href="https://fiscaldata.treasury.gov/americas-finance-guide/national-deficit/"> $1.31 trillion</a> in the first half of fiscal 2025.
"If you get to $100 billion to $200 billion, you'll be pretty lucky," Moody's Chief Economist Mark Zandi told <a href="https://www.cnbc.com/2025/04/01/tariffs-may-raise-much-less-than-white-house-projects-economists-say.html">CNBC</a>, offering a reality check and arguing that tariffs alone won't replace income tax burdens.
The auto sector is already feeling the squeeze.<a href="https://www.reuters.com/business/autos-transportation/ford-hikes-prices-mexico-produced-models-citing-tariffs-2025-05-07/"> Reuters</a> reviewed a memo sent by Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) to dealers on May 7, which said that the company would raise prices by $2,000 on three models assembled in Mexico—the Mustang Mach-E, Maverick, and Bronco Sport—due to new tariffs. <a href="https://d18rn0p25nwr6d.cloudfront.net/CIK-0000037996/f84f5dbe-040c-4931-902d-beeabbb356f0.pdf">Ford is bracing for $2.5 billion</a> in added costs and has suspended its 2025 financial guidance.&nbsp;
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — <a href="https://www.benzinga.com/money/boxabl-scaling-fast-from-spacex-orders-to-600-homes-built-this-60k-foldable-home-may-be-the-future-of-housing">this is your last chance to become an investor for $0.80 per share.</a>
General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) has <a href="https://investor.gm.com/static-files/5522207f-8b91-4788-b1ec-617c2981c3e5">disclosed </a>a projected<a href="https://www.benzinga.com/startups/25/02/43463099/donald-trumps-25-tariff-plan-only-tough-measures-will-level-the-playing-field-kevin-oleary-explains-the-strategy"> tariff </a>exposure of $4 billion to $5 billion for 2025, prompting a downward revision of its annual earnings forecast and a pause on its $4 billion share-buyback program.
Beyond auto, the ripple effect stretches into food and beverage. In Pittsburgh, small businesses like Brew Gentlemen Brewery and Lotus Foods have reported delays, cost spikes, and logistical hurdles that some say echo COVID-era supply chain chaos, according to<a href="https://www.theguardian.com/us-news/2025/may/01/trump-tariffs-pittsburgh-covid-2-0-us-economy"> The Guardian</a>.
Internationally, the situation is escalating. The European Union is preparing a €100 billion ($113 billion) retaliation plan—including tariffs on Boeing aircraft—if U.S.-EU negotiations break down. The move follows the U.S.&#8217;s April 2 decision to impose a 20% tariff on nearly all EU exports, as the<a href="https://www.ft.com/content/42458681-95c4-463e-866d-1c6968e61df6"> Financial Times</a> reported.
Read Next:
<ul class="wp-block-list">
<li>Maximize saving for your retirement and cut down on taxes: <a href="https://www.benzinga.com/money/wideradvisor-retirement-planning">Schedule your free call with a financial advisor to start your financial journey – no cost, no obligation</a>. </li>
<li>Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a></li>
</ul>
Image: Shutterstock

Personal Finance

Trump Says Tariff Money Could 'Replace The Income Tax' — April Customs Collections Hit Record $15.4 Billion As New Duties Take Effect

Telsey Advisory Group analyst Joseph Feldman maintains Dick's Sporting Goods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) with a Outperform and maintains $250 price target.

Telsey Advisory Group Maintains Outperform on Dick's Sporting Goods, Maintains $250 Price Target

Roth Capital analyst Suji Desilva maintains Aeva Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEVA#NASDAQ">AEVA</a>) with a Buy and raises the price target from $6 to $17.

AEVA

Roth Capital Maintains Buy on Aeva Technologies, Raises Price Target to $17

Telsey Advisory Group analyst Cristina Fernandez maintains Arhaus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARHS#NASDAQ">ARHS</a>) with a Market Perform and maintains $10 price target.

ARHS

Telsey Advisory Group Maintains Market Perform on Arhaus, Maintains $10 Price Target

Roth Capital analyst Philip Shen reiterates NEXTracker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXT#NASDAQ">NXT</a>) with a Buy and raises the price target from $55 to $70.

Reiteration

Roth Capital Reiterates Buy on NEXTracker, Raises Price Target to $70

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Citigroup analyst John Yu initiated coverage on WEBTOON Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBTN#NASDAQ">WBTN</a>) with a Buy rating and announced a price target of $11. Webtoon Entertainment shares closed at $8.05 on Wednesday. <a href="https://www.benzinga.com/quote/wbtn/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Zelman &amp; Assoc initiated coverage on Wayfair Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with an Outperform rating. Wayfair shares closed at $38.53 on Wednesday. <a href="https://www.benzinga.com/quote/W/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Zelman &amp; Assoc initiated coverage on Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with an Underperform rating. Williams-Sonoma shares closed at $171.62 on Wednesday. <a href="https://www.benzinga.com/quote/WSM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Roth Capital analyst Taz Koujalgi initiated coverage on Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Neutral rating and announced a price target of $210. Palo Alto shares closed at $190.90 on Wednesday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying WSM stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="587" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15133825/image-186-1024x587.png" alt="" class="wp-image-916939" style="width:636px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15133825/image-186-1024x587.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15133825/image-186-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15133825/image-186-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/15133825/image-186.png 1100w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45405004/jim-cramer-sofi-goes-to-new-highs-recommends-not-buying-this-health-care-stock">Jim Cramer: SoFi Goes To &#8216;New Highs,&#8217; Recommends Not Buying This Health Care Stock</a> </li>
</ul>
Photo via Shutterstock

Initiation

PANW

WBTN

This Williams-Sonoma Analyst Begins Coverage On A Bearish Note; Here Are Top 4 Initiations For Thursday

Roth Capital analyst Leo Mariani downgrades Murphy Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUR#NYSE">MUR</a>) from Buy to Neutral and lowers the price target from $27 to $25.

Roth Capital Downgrades Murphy Oil to Neutral, Lowers Price Target to $25

D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OSTX#AMEX">OSTX</a>) with a Buy and maintains $20 price target.

OSTX

D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target

Roth Capital analyst Leo Mariani downgrades Civitas Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) from Buy to Neutral and lowers the price target from $46 to $34.

CIVI

Roth Capital Downgrades Civitas Resources to Neutral, Lowers Price Target to $34

D. Boral Capital analyst Jason Kolbert maintains CytoSorbents (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSO#NASDAQ">CTSO</a>) with a Buy and maintains $10 price target.

CTSO

D. Boral Capital Maintains Buy on CytoSorbents, Maintains $10 Price Target

Press Releases

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock

Health Care

Mineralys Therapeutics Announces Data from the Phase 2 Advance-HTN Trial of Lorundrosat for the Treatment of Hypertension Has Been Accepted as a Late-Breaking Presentation at the 2025 American College of Cardiology's Annual Scientific Session & Expo

Mineralys Therapeutics Announces Closing of Underwriters' Option to Purchase Additional Shares in Connection with Public Offering of Common Stock

Mineralys Therapeutics to Host KOL Call to Discuss Clinical Data from Launch-HTN and Advance-HTN Pivotal Trials Tuesday, April 1, 2025, at 8:00 AM ET

Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology's Annual Scientific Session & Expo (ACC.25)

Comments

Mineralys Therapeutics

Noticias

Últimas noticias sobre Mineralys Therapeutics (NASDAQ:MLYS) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL